$GILD News

GILD Reports Positive Results From Late-Stage Liver Disease Study

Assessing Gilead Sciences (GILD) Valuation After Recent Share Price Weakness

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Gilead eyes PBC expansion for Livdelzi on positive one-year data

How Investors Are Reacting To Gilead Sciences (GILD) Expanding Liver And Oncology Drug Footprint

Gilead Sciences (GILD) Announces New Results From a Post Hoc Analysis

Gilead Sciences, Inc. (GILD) Gains Attention as Livdelzi Demonstrates Long-Term Efficacy and Safety

Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome

Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)

Gilead Sciences Announces Results Of Phase 3 Study In People With Primary Biliary Cholangitis That Indicated Treatment With Livdelzi Led To Significantly More Patients Achieving Normalization Of Alkaline Phosphatase

Gilead (GILD) to Showcase New Cancer Therapy Data

Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today

Gilead: 'Hold' On Biktarvy Sales Growth And MM Drug Development Program

Gilead (GILD) Wins FDA Approval for First HDV Treatment Hepcludex

Gilead's Livdelzi Shows High And Sustained ALP Normalization In 74% Of Primary Biliary Cholangitis Patients At 24 Months In Phase 3 ASSURE Study

If You Invested $1000 In Gilead Sciences Stock 15 Years Ago, You Would Have This Much Today

Gilead Sciences (GILD) Acquires Tubulis for $3.15B to Expand Oncology Portfolio

Maxim Upgrades Gilead Sciences (GILD) to ‘Buy’

Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference

Is It Time To Reassess Gilead Sciences (GILD) After Strong Multi Year Share Price Gains